Why the Cheapest Medical Equipment Is the Most Expensive: A Procurement Manager’s Take

I’ve been managing capital equipment purchases for a 340-person regional health system in New Jersey for six years. In that time, I’ve reviewed over 400 quotes and signed off on about $2.1 million in medical equipment contracts. And here’s the thing I keep telling our finance team: the cheapest medical equipment quote is usually the most expensive one in the room.

I’m a cost controller. My job is to keep the budget from bleeding. So when I say “cheap isn’t cheap,” I don’t mean it as a slogan. It’s the pattern I see in our procurement system when I audit past purchases. The vendors who scare you with a low number often make their profit back on installation, service, reagents, and downtime.

Start with the sticker price, then do the rest of the math

The conventional procurement advice is to get three quotes and take the lowest. That advice ignores something important: medical devices don’t come with an honest total-cost number on the invoice. The purchase price is the beginning, not the end.

If you’ve ever asked “what is a hematology analyzer?”—it’s the lab instrument that counts and classifies red blood cells, white blood cells, and platelets in a blood sample. For a clinic or a small hospital lab, it’s a daily workhorse. It’s also a perfect example of why initial price can mislead you.

In 2023, I compared two hematology analyzers using quotes we received and public list prices. The cheaper unit was $9,800. The other was $13,400. The $3,600 difference looked like an easy “yes” to the cheaper one—until I ran the consumable numbers. The cheaper analyzer needed reagents that cost $0.46 per test. The other used $0.28 per test. At 350 tests per month, that’s a $756 difference every year just in reagents. Add in service contracts, calibration fluid, and waste disposal, and the “cheap” analyzer cost us about $45,000 over five years. The “expensive” one came in around $41,200. The lower sticker price was the more expensive choice.

That’s the kind of comparison that makes people think I’m doing the vendor’s work for them. I’m not. I’m doing the part of my job that doesn’t fit on a purchase order.

Mammography: when downtime costs more than the machine

A mammography system is another purchase where value matters more than price. We replaced one at our outpatient imaging center in early 2024. One vendor offered a used system for $68,000. Another offered a new system for $95,000, including installation, acceptance testing, and three years of service. The used system looked like a $27,000 win. But our staff would have needed at least 14 days to install and calibrate it. That’s roughly 180 missed screening exams. At our average reimbursement, the lost revenue ate up more than half of the supposed savings. And if the used system failed, we’d have no uptime guarantee—just a phone number.

Let me be clear: I’m not saying used imaging equipment is always a bad idea. I’m saying the sticker price has to be compared with downtime, reinstallation, staff training, and the cost of a canceled patient schedule. Buying a mammography unit without a service plan is like buying a car and discovering the tires, oil changes, and warranty aren’t included.

When I audited our 2023 spending, I found that 62% of our equipment-related budget overruns came from service and consumables, not from the initial purchase price. That number changed how I present vendor comparisons to our CFO. Now every quote goes into the same TCO spreadsheet, with the same categories.

A fundus camera: the hidden cost is patient flow

Fundus cameras are smaller purchases, but they follow the same rule. A fundus camera is a specialized instrument that photographs the retina, optic disc, and retinal blood vessels. It’s used to screen for diabetic retinopathy, monitor glaucoma, and track a range of eye conditions. For a primary care clinic, it’s also a patient-flow tool: the faster the image, the faster the exam.

We tested two models in one of our clinics. The low-cost handheld was $17,500 and worked well for the first three months. Then the autofocus started to drift. The vendor quoted a repair that wasn’t covered under the one-year basic warranty. Meanwhile, the tabletop model we’d turned down—$24,200 with a three-year warranty and remote diagnostics—had a 99.2% uptime over the same period. Seeing the two side by side made me realize something: the question isn’t “What does it cost?” The question is “What happens when it doesn’t work?”

I’m not 100% sure every practice should buy the more expensive unit. If you’re screening only 50 patients a month, a handheld with an extended warranty might be fine. But if the camera sits in the middle of a chronic-disease management program, its failure becomes a bottleneck. And a bottleneck in patient care is a financial problem, not just a clinical one.

What a Hamilton Medical company overview should give you

If you ask me, a company overview is the first thing a procurement person should be skeptical of. A company overview is a brochure. It lists history, locations, and product categories. It doesn’t list first-call fix rates, average response times, or how many service engineers are within a 90-minute drive of your facility. That’s the information that changes the cost math.

If you’ve typed “hamilton-medical” into a search bar, you probably don’t want a corporate timeline—you want to know whether this source can deliver the right equipment and support. The same is true if you’re searching for “hamilton medical group nj.” When I evaluate a supplier, I don’t look at the logo. I look at their service footprint, contract language, and consumable pricing. If a vendor can’t document those, the initial price is just a guess.

For a quick sanity check, here’s what I’m seeing in public pricing as of January 2025: benchtop hematology analyzers range from about $12,000 to $50,000 depending on throughput; fundus cameras range from $15,000 to $35,000; and compact mammography systems run from roughly $70,000 to $180,000. The ranges are not the point. The point is that service contracts on all three can add $3,000 to $15,000 per year. If a vendor won’t separate those costs for you, you’re not comparing offers—you’re comparing guesses.

But what if your budget is only $20,000?

I hear this question a lot: “Easy for you to say—we don’t have the $30,000 option.” I understand. I’ve had to defend tight budgets too. That’s exactly why total cost matters more, not less, when money is scarce. A $2,000 surprise in a $125,000 project is annoying. The same surprise in a $20,000 project is a crisis.

People think expensive vendors charge more because of their brand. The causation usually runs the other way: vendors who invest in service infrastructure can charge more, and they can justify that premium because they reduce the buyer’s total risk. The purchase price is a proxy for that risk, not the whole story.

So if the capital budget is tight, I look for a slightly higher initial quote that includes service, training, and consumable caps. It might not fit the line item as neatly, but it fits the actual budget much better. I’d rather defend a 5% higher capital request than a 30% operating-budget overrun two years from now.

The bottom line: I still compare prices

Let me not be misunderstood. I don’t ignore the initial quote. Price is a constraint, and every dollar matters. But my job is to protect the health system’s money across the life of the device, not just at the moment of purchase. When I choose a slightly higher quote because it includes the right service coverage, I know exactly what I’m defending: a lower total cost per patient test, fewer canceled exams, and a smaller chance of a budget surprise in year two.

The cheapest price isn’t the cheapest purchase. The cheapest purchase is the one whose follow-on costs you can predict and control.

The next time you’re comparing a mammography system, a fundus camera, or a hematology analyzer, ask yourself one question: what happens when it needs service? If the answer is vague, the true cost is still unknown. In medical equipment, the lowest price is the beginning of the analysis, not the end of it.